...
机译:预后生物标志物用IPILIMIMAB在转移性黑色素瘤中的免疫疗法
Department of OncologyOslo University Hospital The Norwegian Radium HospitalOslo Norway;
Department of OncologyOslo University Hospital The Norwegian Radium HospitalOslo Norway;
Department of OncologyOslo University Hospital The Norwegian Radium HospitalOslo Norway;
Department of OncologyOslo University Hospital The Norwegian Radium HospitalOslo Norway;
Institute of Clinical MedicineUniversity of OsloOslo Norway;
Department of OncologyOslo University Hospital The Norwegian Radium HospitalOslo Norway;
Department of OncologyOslo University Hospital The Norwegian Radium HospitalOslo Norway;
Research Institute of Internal MedicineOslo University Hospital RikshospitaletOslo Norway;
Research Institute of Internal MedicineOslo University Hospital RikshospitaletOslo Norway;
Department of Tumor Biology Institute for Cancer ResearchOslo University Hospital The Norwegian;
Research Institute of Internal MedicineOslo University Hospital RikshospitaletOslo Norway;
Department of Tumor Biology Institute for Cancer ResearchOslo University Hospital The Norwegian;
Research Institute of Internal MedicineOslo University Hospital RikshospitaletOslo Norway;
anti‐CTLA‐4; endostatin; Gal3BP; immunotherapy; melanoma;
机译:预后生物标志物用IPILIMIMAB在转移性黑色素瘤中的免疫疗法
机译:预后和预测性生物标志物对转移性黑色素瘤患者免疫治疗的益处
机译:预后和预测性生物标志物对转移性黑色素瘤患者免疫治疗的益处
机译:靶向蛋白质组学管道揭示了潜在的生物标志物,用于诊断胸腔积液中转移性肺癌
机译:预测转移性黑色素瘤中抗PD-1免疫疗法的反应。
机译:ipilimumab免疫治疗转移性黑色素瘤的预后生物标志物
机译:伊匹木单抗治疗转移性黑色素瘤患者的预后和毒性生物标志物。